Everything below concerns NR1D1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
However, in cases of severe kidney dysfunction the CrCl rate will overestimate the GFR, because hypersecretion of creatinine by the proximal renal tubules will account for a larger fraction of the total creatinine cleared. Ketoacids, cimetidine, and trimethoprim reduce creatinine tubular secretion and therefore increase the accuracy of the GFR estimate, in particular in severe kidney dysfunction. (In the absence of secretion, creatinine behaves like inulin.) An alternative estimation of kidney function can be made when interpreting the blood plasma concentration of creatinine along with that of urea. BUN-to-creatinine ratio (the ratio of blood urea nitrogen to creatinine) can indicate other problems besides those intrinsic to the kidney; for example, a urea concentration raised out of proportion to the creatinine may indicate a prerenal problem, such as volume depletion. Counterintuitively, supporting the observation of higher creatinine production in women than in men, and putting into question the algorithms for GFR that do not distinguish for sex, women have higher muscle protein synthesis and higher muscle protein turnover across their life span. As HDL supports muscle anabolism, higher muscle protein turnover links increased creatine to the generally higher serum HDL in women compared with serum HDL in men.
In 1933, Prince Wilhelm, the eldest son of Crown Prince Wilhelm and second in line of succession, renounced his dynastic rights under house law upon his marriage to the non-royal Dorothea von Salviati. Shortly before Prince Wilhelm was killed in action in May 1940, Wilhelm II recognized his wife and daughters (Felicitas and Christa) as dynastic members, styling them Princesses of Prussia. Following his elder brother's 1933 renunciation, Prince Louis Ferdinand became the heir to the headship, succeeding his father in 1951. His two eldest sons both forfeited their dynastic succession rights under house law upon contracting unequal marriages: Prince Friedrich Wilhelm renounced his rights in 1967 (marrying Waltraud Freytag), and Prince Michael did so in 1966 (marrying Jutta Jörn). His third son, Prince Louis Ferdinand Jr., died in 1977 following a severe military training accident, leaving an infant son, Georg Friedrich. When Prince Louis Ferdinand died in 1994, the headship of the family passed to his grandson, Georg Friedrich. However, his succession as sole principal beneficiary of the family trust (*Kronvermögen*) was challenged in court by his uncles, Princes Friedrich Wilhelm and Michael. They argued that their prior renunciations were invalid and that conditioning testamentary inheritance on historical equal-marriage rules violated German constitutional protections regarding marriage equality and freedom of spouse selection. The dispute led to a decade of civil litigation across multiple jurisdictions.
The toxins cause direct damage to the glomeruli in the kidneys as well as causing protein deposits in Bowman's capsule. Or the kidneys may be indirectly damaged by envenomation due to shock, clearance of toxic substances such as immune complexes, blood degradation products, or products of muscle breakdown (rhabdomyolysis). In venom-induced consumption coagulopathy, toxins in snake venom promote hemorrhage via activation, consumption, and subsequent depletion of clotting factors in the blood. These clotting factors normally work as part of the coagulation cascade in the blood to form blood clots and prevent hemorrhage. Toxins in snake venom (especially the venom of New World pit vipers (the family crotalina)) may also cause low platelets (thrombocytopenia) or altered platelet function also leading to bleeding. Snake venom is known to cause neuromuscular paralysis, usually as a flaccid paralysis that is descending; starting at the facial muscles, causing ptosis or drooping eyelids and dysarthria or poor articulation of speech, and descending to the respiratory muscles causing respiratory compromise. The neurotoxins can either bind to and block membrane receptors at the post-synaptic neurons or they can be taken up into the pre-synaptic neuron cells and impair neurotransmitter release. Venom toxins that are taken up intra-cellularly, into the cells of the pre-synaptic neurons are much more difficult to reverse using anti-venom as they are inaccessible to the anti-venom when they are intracellular.
On February 4, 2025, United States president Donald Trump proposed a US takeover of the Gaza Strip and the relocation of its Palestinian inhabitants. Officially known as the Gaza Reconstitution, Economic Acceleration and Transformation Trust (or GREAT Trust), the proposal was announced by Trump during a press conference between him and Israeli prime minister Benjamin Netanyahu, and occurred during a ceasefire in the Gaza war, fought between Israel and Hamas-led Palestinian militants. Trump expressed his vision to redevelop the territory into the "Riviera of the Middle East". The proposal called for the forced displacement of approximately two million Palestinians to neighboring lands, and would also have required the removal of over 50 million tonnes of debris and unexploded ordnance. When asked how the territory would be acquired, Trump claimed the US would "take it". The proposal received negative receptions from several nations and organizations, contrasting with strong support from Netanyahu.
Sources: en.wikipedia.org
Fentanyl acts on opioid receptors. These receptors are G-protein-coupled receptors, which contain seven transmembrane portions, intracellular loops, extracellular loops, intracellular C-terminus, and extracellular N-terminus. The extracellular N-terminus is important in differentiating different types of binding substrates. When fentanyl binds, downstream signaling leads to inhibitory effects, such as decreased cAMP production, decreased calcium ion influx, and increased potassium efflux. This inhibits the ascending pathways in the central nervous system to increase pain threshold by changing the perception of pain; this is mediated by decreasing propagation of nociceptive signals, resulting in analgesic effects. The affinity of fentanyl to the μ-opioid receptor is similar to that of morphine. The reasons for fentanyl's increased potency in vivo are unclear, however differences in efficacy and pharmacokinetics may be involved. It has high lipid solubility, allowing it to penetrate more easily the central nervous system. It attenuates "second pain" with primary effects on slow-conducting, unmyelinated C-fibers and is less effective on neuropathic pain and "first pain" signals through small, myelinated A-fibers. Fentanyl can produce the following clinical effects strongly, through μ-receptor agonism:
=== Form === Military grade C-4 is commonly packaged as the M112 demolition block. The demolition charge M112 is a rectangular block of Composition C-4 about 2 by 1.5 inches (51 mm × 38 mm) and 11 inches (280 mm) long, weighing 1.25 lb (570 g). The M112 is wrapped in a sometimes olive color Mylar-film container with a pressure-sensitive adhesive tape on one surface. The M112 demolition blocks of C-4 are commonly manufactured into the M183 "demolition charge assembly", which consists of 16 M112 block demolition charges and four priming assemblies packaged inside military Carrying Case M85. The M183 is used to breach obstacles or demolish large structures where larger satchel charges are required. Each priming assembly includes a five-or-twenty-foot (1.5 or 6.1 m) length of detonating cord assembled with detonating cord clips and capped at each end with a booster. When the charge is detonated, the explosive is converted into compressed gas. The gas exerts pressure in the form of a shock wave, which demolishes the target by cutting, breaching, or cratering. Other forms include the mine-clearing line charge and M18A1 Claymore mine.
=== Psychoactive ingredients === According to the United Nations Office on Drugs and Crime (UNODC), "the amount of THC present in a cannabis sample is generally used as a measure of cannabis potency." The three main forms of cannabis products are the flower/fruit, resin (hashish), and oil (hash oil). The UNODC states that cannabis often contains 5% THC content, resin "can contain up to 20% THC content", and that "Cannabis oil may contain more than 60% THC content." Studies have found that the potency of illicit cannabis has greatly increased since the 1970s, with THC levels rising and CBD levels dropping. It is unclear, however, whether the increase in THC content has caused people to consume more THC or if users adjust based on the potency of the cannabis. It is likely that the higher THC content allows people to ingest less tar. At the same time, CBD levels in seized samples have lowered, in part because of the desire to produce higher THC levels and because more illegal growers cultivate indoors using artificial lights. This helps avoid detection but reduces the CBD production of the plant. Australia's National Cannabis Prevention and Information Centre (NCPIC) states that the buds (infructescences) of the female Cannabis plant contain the highest concentration of THC, followed by the leaves. The stalks and seeds have "much lower THC levels". The UN states that the leaves can contain ten times less THC than the buds, and the stalks 100 times less THC. After revisions to cannabis scheduling in the UK, the government moved cannabis back from a class C to a class B drug.
Sources: en.wikipedia.org
Iodine absorbed by the body is almost completely stored in the thyroid gland and has a biological half-life of about 120 days. If the iodine is radioactive (131I), it can irradiate and damage the thyroid gland in high doses during this time. Because the thyroid gland can only absorb a limited amount of iodine, prophylactic administration of non-radioactive iodine may result in iodine blockade. Potassium iodide in tablet form (colloquially known as "iodine tablets") reduces the uptake of radioactive iodine into the thyroid by a factor of 90 or more, thus acting as a radioprotector. All other radiation damage remains unaffected by taking iodine tablets. In Germany, the Potassium Iodide Ordinance (KIV) was enacted in 2003 to ensure "the supply of the population with potassium iodide-containing medicines in the event of radiological incidents". § 1 kiv (in German) Potassium iodide is usually stored in communities near nuclear facilities for distribution to the population in the event of a disaster. People over the age of 45 should not take iodine tablets because the risk of side effects is higher than the risk of developing thyroid cancer. In Switzerland, as a precautionary measure, tablets have been distributed every five years since 2004 to the population living within 20 km of nuclear power plants (from 2014, 50 km). In Austria, large stocks of iodine tablets have been kept in pharmacies, kindergartens, schools, the army and the federal reserve since 2002.
== Biosynthesis == The peptidoglycan monomers are synthesized in the cytosol and are then attached to a membrane carrier bactoprenol. Bactoprenol transports peptidoglycan monomers across the cell membrane where they are inserted into the existing peptidoglycan.
== Analogs == Structural analogs of desmethylprodine with different N-substituents than a methyl group on the piperidine have been investigated. Several of these have significantly greater in vitro potency compared to desmethylprodine.
Biomimetics is a field that aims to produce materials and systems that replicate those present in nature. In the context of tissue engineering, this is a common approach used by engineers to create materials for these applications that are comparable to native tissues in terms of their structure, properties, and biocompatibility. Material properties are largely dependent on physical, structural, and chemical characteristics of that material. Subsequently, a biomimetic approach to system design will become significant in material integration, and a sufficient understanding of biological processes and interactions will be necessary. Replication of biological systems and processes may also be used in the synthesis of bio-inspired materials to achieve conditions that produce the desired biological material. Therefore, if a material is synthesized having the same characteristics of biological tissues both structurally and chemically, then ideally the synthesized material will have similar properties. This technique has an extensive history originating from the idea of using natural phenomenon as design inspiration for solutions to human problems. Many modern advancements in technology have been inspired by nature and natural systems, including aircraft, automobiles, architecture, and even industrial systems. Advancements in nanotechnology initiated the application of this technique to micro- and nano-scale problems, including tissue engineering.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.